Promotora intervention for metabolic and mental health to reduce type 2 diabetes risk: a pilot randomized controlled trial.

The objective of this study was to develop and evaluate a novel behavioral intervention (PRIME2) that integrates evidence-based approaches for reducing diabetes risk and perceived stress. We conducted a pilot randomized controlled trial of the 16-session PRIME2 intervention vs. usual care among 40 Spanish-speaking Latinx adults with prediabetes and body mass index (BMI) ≥ 25 kg/m.

Heat stable and intrinsically sterile liquid protein formulations.

Over 80% of biologic drugs, and 90% of vaccines, require temperature-controlled conditions throughout the supply chain to minimize thermal inactivation and contamination. This cold chain is costly, requires stringent oversight, and is impractical in remote environments. Here, we report chemical dispersants that non-covalently solvate proteins within fluorous liquids to alter their thermodynamic equilibrium and reduce conformational flexibility.

Assessment of the available evidence for the use of 7-Tesla (T) magnetic resonance imaging (MRI) in neurological and musculoskeletal disorders, with comparison to 3-T and 1.5-T MRI: A systematic scoping review.

Background: Ultra-high-field magnetic resonance imaging (MRI) at a field strength of 7 Tesla (T) has marked a significant milestone in diagnostic imaging since it was approved for clinical use in 2017. Despite the potential to improve image analysis by advances in signal-to-noise ratio, and improved spatial resolution and metabolic imaging, the clinical implementation of 7-T MRI remains limited. Factors that contribute to this limited availability are the high price, the operating costs, the need for specifically educated personnel, and lack of evidence of clinical benefit.

A polygeneric immunogen composed of 22 venoms from sub-Saharan African snakes to expand the neutralization scope of the EchiTAb-plus-ICP antivenom.

Recent research suggests that a polygeneric immunogen made from the venoms of the most medically important viperid and elapid snakes in sub-Saharan Africa could elicit a broader antibody response in horses compared to the current EchiTAb-plus-ICP antivenom, especially against neurotoxic elapid venoms. To test this, 25 horses that have been regularly immunized to produce this antivenom were reimmunized with an immunogen containing 22 venoms from various snake species from the genera , , , and both spitting and non-spitting . The plasma collected from these horses was processed using the caprylic acid method to produce an industrial-scale freeze-dried antivenom.